Interpace Biosciences Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Interpace Biosciences stock.
View analyst ratings for Interpace Biosciences or view top-rated stocks.

Wall Street analysts have given Interpace Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Interpace Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Interpace Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Interpace Biosciences.

Interpace Biosciences, Inc. (NASDAQ:IDXG) posted its earnings results on Tuesday, March, 30th. The business services provider reported ($2.00) EPS for the quarter, missing the Zacks' consensus estimate of ($1.32) by $0.68. Interpace Biosciences had a negative trailing twelve-month return on equity of 251.52% and a negative net margin of 115.30%.
View Interpace Biosciences' earnings history.

Interpace Biosciences updated its fourth quarter 2020 Pre-Market earnings guidance on Wednesday, January, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9-10 million, compared to the consensus revenue estimate of $8.65 million.

3 equities research analysts have issued twelve-month target prices for Interpace Biosciences' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Interpace Biosciences' share price to reach $9.33 in the next year. This suggests a possible upside of 20.4% from the stock's current price.
View analysts' price targets for Interpace Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Interpace Biosciences include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of IDXG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."

One share of IDXG stock can currently be purchased for approximately $7.75.

Interpace Biosciences has a market capitalization of $31.81 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis.

Interpace Biosciences employs 176 workers across the globe.

The official website for Interpace Biosciences is www.interpace.com.

Interpace Biosciences is headquartered at MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054.

Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]